HC Wainwright Issues Optimistic Forecast for RLAY Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Investment analysts at HC Wainwright lifted their Q2 2025 EPS estimates for Relay Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.49) per share for the quarter, up from their previous estimate of ($0.53). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for Relay Therapeutics' current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Relay Therapeutics' Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.49) EPS and FY2025 earnings at ($1.92) EPS.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.04. The firm had revenue of $7.68 million for the quarter, compared to analyst estimates of $0.01 million. During the same period last year, the firm posted ($0.62) EPS. The business's revenue was down 23.0% compared to the same quarter last year.

A number of other equities research analysts have also recently weighed in on RLAY. Stifel Nicolaus cut their price objective on shares of Relay Therapeutics from $27.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. The Goldman Sachs Group cut their price objective on shares of Relay Therapeutics from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Wells Fargo & Company began coverage on shares of Relay Therapeutics in a research note on Thursday, April 17th. They set an "equal weight" rating and a $4.00 price objective on the stock. Finally, Guggenheim cut their price objective on shares of Relay Therapeutics from $30.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.67.

Relay Therapeutics Stock Performance

Shares of RLAY opened at $3.01 on Monday. Relay Therapeutics has a 1 year low of $1.78 and a 1 year high of $10.72. The company has a market cap of $516.05 million, a price-to-earnings ratio of -1.15 and a beta of 1.65. The firm has a fifty day moving average of $2.92 and a 200-day moving average of $4.03.

Insiders Place Their Bets

In other Relay Therapeutics news, insider Peter Rahmer sold 10,739 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $3.00, for a total value of $32,217.00. Following the sale, the insider now directly owns 390,081 shares in the company, valued at approximately $1,170,243. The trade was a 2.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sanjiv Patel sold 61,422 shares of the business's stock in a transaction dated Wednesday, April 23rd. The stock was sold at an average price of $2.97, for a total transaction of $182,423.34. Following the completion of the sale, the chief executive officer now owns 821,667 shares in the company, valued at approximately $2,440,350.99. This trade represents a 6.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 309,826 shares of company stock worth $1,099,380. 4.87% of the stock is owned by corporate insiders.

Institutional Trading of Relay Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RLAY. Barclays PLC raised its holdings in Relay Therapeutics by 118.4% during the 3rd quarter. Barclays PLC now owns 251,819 shares of the company's stock worth $1,783,000 after buying an additional 136,541 shares during the period. Franklin Resources Inc. raised its holdings in Relay Therapeutics by 3,883.8% during the 3rd quarter. Franklin Resources Inc. now owns 1,396,842 shares of the company's stock worth $9,429,000 after buying an additional 1,361,779 shares during the period. SG Americas Securities LLC raised its holdings in Relay Therapeutics by 40.8% during the 4th quarter. SG Americas Securities LLC now owns 77,557 shares of the company's stock worth $320,000 after buying an additional 22,473 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Relay Therapeutics by 37.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 35,491 shares of the company's stock worth $146,000 after buying an additional 9,740 shares during the period. Finally, Savant Capital LLC acquired a new stake in Relay Therapeutics during the 4th quarter worth about $120,000. Institutional investors and hedge funds own 96.98% of the company's stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.